Dhvanit Vijapura, MD
Psychiatry · Panama City Beach, FLNPI 1558338202
Payments from drug & device makers
Across 418 payments — averaging $312.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$64K
- AbbVie$61K
- Johnson & Johnson$601
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$600
- Neuronetics, Inc.$597
- Otsuka America Pharmaceutical, Inc.$491
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$106,64582%
- Travel & lodging$13,83811%
- Food & beverage$9,8768%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 123 | $64,323 |
| AbbVie(2 entities) | 160 | $61,159 |
| Johnson & Johnson | 17 | $601 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $600 |
| Neuronetics, Inc. | 4 | $597 |
| Otsuka America Pharmaceutical, Inc. | 16 | $491 |
| Axsome Therapeutics, Inc. | 5 | $391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $335 |
| Idorsia Pharmaceuticals US Inc | 10 | $314 |
| Vanda Pharmaceuticals Inc. | 3 | $251 |
| Eisai Inc. | 15 | $221 |
| Alkermes, Inc. | 2 | $209 |
| Lundbeck LLC | 10 | $185 |
| Supernus Pharmaceuticals, Inc. | 2 | $139 |
| Indivior Inc. | 5 | $116 |
| Neurocrine Biosciences, Inc. | 1 | $116 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $104 |
| Avanir Pharmaceuticals, Inc. | 1 | $100 |
| Neos Therapeutics, LP | 3 | $62 |
| Braeburn Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Shire North American Group Inc | 1 | $23 |
| Tris Pharma Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$130,451 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 17 | $2,396 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $1,398 |
| Clonazepam | 47 | $416 |
| Duloxetine Hcl | 31 | $386 |
| Trazodone Hcl | 40 | $210 |
| Alprazolam | 25 | $175 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Panama City Beach
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.